Our first-of-its-kind oral enzyme platform has the power to treat patients with severe and underserved metabolic disorders by breaking down harmful substances in the gastrointestinal (GI) tract, such as oxalate and urate. With our targeted approach, our therapeutics have the potential to reduce the elevated levels of harmful metabolites before they result in severe, debilitating consequences including kidney stones, gout, chronic kidney disease, and end-stage kidney disease.
Enteric hyperoxaluria is a more severe type of secondary hyperoxaluria, since the underlying GI disorder predisposes patients to chronic excess oxalate absorption. Primary hyperoxaluria differs from enteric hyperoxaluria in that it is an inherited defect of oxalate metabolism.
How Allena can help
Watch Jan tell his story
While there is currently no approved treatment for enteric hyperoxaluria, Allena’s first-in-class non-absorbed oxalate-degrading enzyme has the potential to prevent downstream consequences like kidney stones.
To learn more about enteric hyperoxaluria, check out this podcast presented by Urology Times.
Hyperuricemia and Gout
Hyperuricemia is an elevated urate (uric acid) level in the blood. Elevated urate levels in the blood result from either overproduction or insufficient excretion. Two of the most common clinical manifestations of high urate in the blood are gout and kidney stones. In the case of gout, urate crystals activate an inflammatory response in joints, resulting in sudden attacks marked by stiffness, swelling, and burning pain.
Existing treatments for hyperuricemia and gout have safety concerns, particularly for patients with reduced kidney function.
Allena’s first-in-class non-absorbed urate-degrading enzyme has the potential to treat hyperuricemia and lower the risk of complications associated with elevated urate.
Learn more about our novel oral enzyme platform in the scientific literature.